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c Bristol Royal Hospital for Children, Department of Paediatric Cardiothoracic Surgery, Bristol, UKh i g h l i g h t s Prophylactic glucocorticoids are widely used to modulate the inﬂammatory response and treat presumed relative adrenal insufﬁciency in children
undergoing heart surgery.
 There is wide variability between centre and physician's preference in the timing, dose, route or type of steroid to be administered.
 There is an intense debate about prophylactic steroid use and their effect on the clinical outcomes.
 The weight of the current evidence for prophylactic, perioperative steroid administration suggests they do not unequivocally improve clinical endpoints.
 A large, multicentre prospective randomized controlled trial is needed to clarify the role of steroids in paediatric heart surgery.a r t i c l e i n f o
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A best evidence topic was written according to a structured protocol. The question addressed was: Is the
use of prophylactic, perioperative steroids associated with better clinical outcomes following heart
surgery in neonates? Altogether, 194 papers were found using the reported search, of which 8 repre-
sented the best evidence to answer the clinical question. One study found improved hospital survival in
the group without steroids. Steroids increased infection in one large retrospective study. Incidence of
hyperglycaemia was increased in the steroid group in 2 out of 5 studies. Use of steroids was associated
with a shorter duration of ventilation and better oxygenation in one study. Postoperative steroid infusion
was associated with reduced low cardiac output syndrome, inotrope requirement and less ﬂuid retention
in two controlled trials in which all patients received preoperative steroid. High dose steroid was
associated with renal dysfunction in one study, comparing single versus double dose steroid prophylaxis.
Steroid non-recipients had a shorter intensive care length of stay in 2 out of 7 studies. We conclude that
use of steroids perioperatively does not unequivocally improve clinical outcome in neonatal heart sur-
gery. A large, multicentre prospective randomized controlled trial is needed to clarify the role of steroids
in paediatric heart surgery.
© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
A best evidence topic was constructed according to a structured
protocol. This is fully described in a previous publication in the
IJS([1]).rgery, University Bristol Hos-
ulu).
vier Ltd on behalf of IJS Publishi2. Three-part question
In neonates undergoing heart surgery with cardiopulmonary
by-pass (CPB) is prophylactic use of perioperative steroids associ-
ated with better clinical outcomes?3. Clinical scenario
You are the registrar scrubbing for an arterial switch operation
in a 14 days old neonate. You notice the anaesthetist adminis-
tering dexamethasone before induction. The consultant explainsng Group Ltd. This is an open access article under the CC BY license (http://
D. Fudulu et al. / Annals of Medicine and Surgery 9 (2016) 67e7168that he gives steroids in all neonates to suppress systemic in-
ﬂammatory response and prevent effects of potential adrenal
insufﬁciency. However, you scrubbed in similar cases and other
anaesthetists do not give steroids at all. You ask yourself if the use
of perioperative steroids improves clinical outcomes following
heart surgery in neonates? You resolve to check the literature
yourself.
4. Search strategy
Medline database using PubMed interface, search ﬁeld: title/
abstract.
“(steroid OR corticosteroid OR methylprednisolone OR dexa-
methasone OR hydrocortisone) AND (neonate OR neonatal OR
children OR pediatric) AND (by-pass OR cardiopulmonary bypass
OR cardiac surgery OR cardiac surgical procedure OR heart surgery
OR congenital heart disease OR pediatric heart surgery)”.
5. Search outcome
We found 194 papers using the reported search. From these, 8
papers were identiﬁed that provided the best evidence to answer
the question. The main outcome of these papers are presented in
Table 1.
6. Results
This evidence review focuses on prophylactic, perioperative
steroid regimes for neonatal cardiac surgery. The abrupt interrup-
tion of maternal corticotropin releasing factor and cortisol at
parturition and the immaturity of the hypothalamic-pituitary axis
have been related to the reduced ability of neonates to mount an
adequate stress response [2]. There is no consensus in diagnosing
adrenocortical insufﬁciency in children and correlation with clin-
ical outcome is controversial [2]. Cardiac surgery with use of car-
diopulmonary bypass (CPB) provokes a systemic inﬂammatory
response. Steroids have been widely used to mitigate potential
deleterious effects of systemic inﬂammation [3,4]. However, the
impact of steroids on clinical outcomes following neonatal heart
surgery remains unclear.
We found only two randomized controlled trials assessing the
effect of steroids versus no steroids on clinical outcomes [5,6] in
neonates. These trials had a small sample size and were single
centre. The majority of the studies were retrospective, three of
them being multicentre on large cohorts [3,4,7]. There was het-
erogeneity among the studies in the clinical outcomes measured.
Most studies measured: early mortality, ventilator duration,
infection rates, hyperglycaemia and insulin requirement, low car-
diac output prevalence, ﬂuid balance and intensive care unit (ICU)
length of stay. Furthermore, we found variability in the type, dose
and route of steroid regimen. This is similar to previous surveys of
steroid use [8,9].
Keski-Nisula et al. [6], randomized 40 neonates to either
receiving methylprednisolone at induction or placebo. In the ste-
roid group, blood glucose levels were signiﬁcantly higher compared
to placebo. There was no difference in early mortality, inotropic
score, serum lactate, duration of ventilation or ICU stay.
Graham et al. [10], randomized neonates to receive methyl-
prednisolone as either 2-dose (n ¼ 39), being 8 h preoperatively
and included to the CPB prime, or single dose (n ¼ 37) being
included in the CPB prime only. The 2-dose steroid cohort had
signiﬁcantly higher serum creatinine and reduced diuresis. Mor-
tality, infection rates, insulin requirements, inotropic requirement,ﬂuid balance, duration of mechanical ventilation, ICU and hospital
stay did not differ between the groups.
Robert et al. [5], randomized 40 neonates undergoing cardiac
surgery with CPB to either postoperative hydrocortisone infusion
for 5 days (n ¼ 19) or placebo (n ¼ 21). The hydrocortisone group
had improved ﬂuid balance, urine output and inotropic score. No
signiﬁcant differences were found in: mortality, ventilator-free
days, hospital length of stay, kidney function, antibiotic use for
suspected infections or blood glucose levels.
Pasquali et al. [3], in a multivariate analysis of the largest pop-
ulation to date: 46730 children (10018 neonates) undergoing car-
diac surgery, compared outcomes between steroid recipients and
non-recipients. In the neonatal analysis, steroids increased ICU
stay and the use of insulin, however there were no differences in
infection rates, duration of ventilation or early mortality.
Pasquali et al. [4] analysed steroid use in 3180 neonates un-
dergoing heart surgery. Therewas no signiﬁcantmortality or length
of stay difference between any methylprednisolone regimens
versus no steroids. The authors stratiﬁed the neonates using a risk
score and performed subgroup analyses. The lower surgical risk
group had a signiﬁcant association with infection across all steroid
regimens.
Elhoff et al. [7], using data from a trial database, analysed out-
comes following the Norwood procedure in neonates that received
intraoperative steroids (n ¼ 498) compared to non-recipients
(n ¼ 51). In the univariate analysis non steroid recipients had bet-
ter survival but longer ICU and hospital stays. In multivariate
analysis, hospital survival again trended toward favouring the non-
steroid group, while length of stays, ECMO, infection and renal
failure rates no longer differed statistically.
Dreher et al. [11] compared outcomes from neonates undergo-
ing heart surgery with (n ¼ 55) and without (n ¼ 58) methyl-
prednisolone added to the CPB prime. There were no differences in
clinical outcomes (including length of stay, ventilation require-
ment, infection and mortality) between both groups.
Ando et al. [12] enrolled 20 neonates undergoing biventricular
repair. Ten neonates were assigned to receive either hydrocortisone
infusion after bypass or placebo infusion. The placebo group had a
reduction in the left ventricular shortening fraction, had higher
inotropic requirements and lactate levels compared to the steroid
groups. Furthermore, steroid supplementation was associated with
less body oedema, higher blood oxygenation and shorter duration
of ventilation. There was no difference in renal failure or blood
glucose levels.7. Clinical bottom line
The majority of the studies suggest that perioperative steroid
use does not affect early mortality in neonates undergoing heart
surgery. One large retrospective study highlighted increased
infection in steroid recipients. A few small studies suggested peri-
operative steroids protected against low cardiac output syndrome
and reduced ﬂuid retention. One small study demonstrated
reduced ventilation times and better oxygenation in the steroid
group while the rest of the papers showed no difference. In two
studies, steroid use increased ICU stay. One study suggested
worsening of the renal function in the high dose steroid group.
Given the weight of current evidence, prophylactic, perioperative
steroid administration for neonatal heart surgery does not un-
equivocally improve clinical endpoints. A large, multicentre pro-
spective randomized controlled trial is needed to clarify the role of
steroids in paediatric heart surgery.
Table 1
Best evidence papers.
Author, date and
country
Patient group Study type and level
of evidence
Outcomes Key results Comments
Keski-Nisula et al., June
2013,
Ann Thorac Surg,
Finland (6)
40 neonates
randomized into 2
groups: 1 group
received intravenous
methylprednisolone
(30 mg/kg of
methylprednisolone)
and the other a placebo.
Double blinded PRCT
(Level 2)
Blood glucose levels
lactate, inotropic score,
lactate, duration of
mechanical ventilation,
length of ICU stay,
mortality at 30 days.
Blood glucose levels:
methylprednisolone (MP)
group (11.6 ± 3.0) vs placebo
group (8.7 ± 2.9), p ¼ 00.5.
MP group vs. Placebo: early
mortality (0 vs 3, p ¼ 0.231),
inotrope score (15.2 ± 8.2 vs.
16.5 ± 9.6, p ¼ 0.645), lactate
levels (2.7 ± 1.0 vs.
2.1 ± 0.8,p ¼ 0.069), duration of
ventilation (5.6 4.2 vs. 5.7 ± 4.6,
p ¼ 0.998) or length of ICU stay
(9.3 ± 5.2 vs. 8.2 ± 4.9,
p ¼ 0.515).
No ﬂuid balance or renal
function outcomes.
Graham et al., May
2011, J Thorac
Cardiovasc Surg, USA
(10)
76 neonates assigned to
receive either two-dose
(8 h preoperatively and
operatively, n ¼ 39) or
single dose
(operatively ¼ 37) of
methylprednisolone
(30 mg/kg per dose)
Double blinded PRCT
(Level 2)
Low cardiac output,
serum creatinine,
postoperative diuresis,
infection, insulin
requirements,
postoperative diuresis,
death at 30 days,
inotropic score, ﬂuid
balance, duration of
mechanical ventilation,
intensive care unit and
hospital stay.
Single vs two dose MP: serum
creatinine (0.53 ± 0.12 mg/dl,
p ¼ 0.03 vs. 0.61 ± 0.18 mg/dl
p ¼ 0.03, between-group
differential urine output
(96 ± 49 ml, p ¼ 0.05), low
cardiac output syndrome
incidence (46% (17/37) vs. 38%
(15/39), p ¼ 0.51), infection
rates: 5 (14%) vs. 5 (13%),
p ¼ 0.96; insulin drip 0 vs. 3
(8%), p ¼ 0.24; highest lactate
(mmol/L): 3.8 ± 2.4 vs 5.2 ± 3.5,
p ¼ 0.05; total ﬂuid in at
36 h (mL) 575 ± 145 vs.
586 ± 156, p ¼ 0.77; total ﬂuid
out at 36 h (mL): 600 ± 250 vs.
558 ± 203, p ¼ 0.43; duration of
mechanical ventilation:
5.8 ± 7.9 6.8 ± 9.5, p ¼ 0 0.21;
intensive care unit stay:
11.0 ± 18.5 vs. 10.8 ± 12.8,
p ¼ 0.19, hospital stay: 23 ± 25
vs. 22 ± 15 0.34, p ¼ 0.34.
Single versus double dose
steroid study design.
Robert et al., Sept 2015,
Pediatr. Crit Care
Med, USA (5)
40 neonates were
randomized: 19 to
hydrocortisone
infusion or 21 to
placebo infusion. The
steroid group had a
hydrocortisone bolus
(50 mg/m2) after
weaning from CPB
followed by a 48 h
hydrocortisone
infusion tapered over 3
days (40 mg/m2/
d  24 h,30 mg/m2/
d  12 h, 20 mg/m2/
d  12 h,10 mg/m2/
d  24 h, then stop)
Double-blinded PRCT
(Level 2)
Low cardiac output,
ﬂuid balance, urine
output
syndrome, inotropic
score, mortality,
duration of ventilation,
length of stay on
intensive care unit,
renal failure, antibiotics
use for infection, blood
glucose.
Hydrocortisone vs. placebo
group: low cardiac output
syndrome (5/19 (26%) vs. 12/21
(57%), p ¼ 0.049), negative net
ﬂuid balance at 48 h (114 vs
64 ml/kg; p ¼ 0.01), urine
output at 0e24 h (2.7 vs 1.2 ml/
kg/hr; p¼ 0.03), mortality (0 vs.
3, p ¼ 0.23), time until ﬁrst
extubation: 51 (interquartile
range (IQR), 34e83) vs. 55 (IQR,
21e195), p ¼ 0.7; hospital
length of stay: 19 (IQR, 9e24)
vs. 13.5 (IQR, 9e24); acute
kidney injury: 7 (37%) vs. 7
(33%), p ¼ 1, antibiotics for
suspected infection: 7 (37%) vs.
8 (38%), p ¼ 1; blood glucose
levels: 10 (53%) vs. 15 (71%),
p ¼ 0.3.
Both arms received
methylprednisolone (10 mg/kg)
8 h and 1 h prior to their
operations. No patient received
intraoperative steroids.
The hydrocortisone group was
weaned off vasopressors sooner
with a difference in inotrope-
free subjects seen after 48 h
(p ¼ 0.033).
Pasquali et al.,
Circulation,
November 2010, USA
(3)
46730 children (10018
neonates) - outcomes
between steroids
recipients (54%) and
non-recipients were
compared. Multivariate
analysis, adjusted for
propensity score and
individual covariates
was used. Patients were
stratiﬁed using the Risk
Adjustment in
Congenital Heart Score.
Observational study
(Level 3)
ICU length of stay, use
of insulin, In-hospital
mortality, duration of
ventilation,
postoperative length of
stay and infection.
Least square means difference:
steroids vs no steroid (adjusted
outcomes): ICU length of
stay ¼ 2.5 (1.34e3.66,
p < 0.001); postoperative
insulin: 2.32 (1.97e2.73),
p < 0.001); duration of
ventilation ¼ 1.11 (2.47
e0.25),p ¼ 0.11;
infection ¼ 0.85 (0.68e1.05,
p ¼ 0.14
Mortality, odds ratio (95%
conﬁdence interval): 1.07 (0.89
e1.27), p ¼ 0.48.
Steroid dose and regimens not
reported.
No outcomes on inotrope
requirements, low cardiac
output syndrome, ﬂuid
retention or renal failure.
(continued on next page)
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Table 1 (continued )
Author, date and
country
Patient group Study type and level
of evidence
Outcomes Key results Comments
Pasquali et al.,
Pediatrics. February
2012, 2012, USA (4)
3180 neonates: 22%
received
methylprednisolone on
both the day before and
day of surgery, 12% on
the day before surgery
only, and 28% on the
day of surgery only; 38%
did not receive any
steroids.
Multicentre retrospective
study
(Level 3)
In-hospital mortality,
total length of stay, ICU
length of stay, infection.
Adjusted postoperative
outcomes meyhylprednisolone
receipients compared to non-
steroid recipients:
In hospital mortality, (adjusted
odds ratio 95% CI): both day of/
before surgery 1.00 (0.66
e1.50), p ¼ 0.99, day before
surgery 0.95 (0.60e1.52),
p ¼ 0.84, day of surgery 1.28
(0.93e1.75), p ¼ 0.13.
Total length of stay, (adjusted
odds ratio, 95% CI): both day of/
before surgery 0.95 (0.83
e1.10), p ¼ 0 0.51, Day before
surgery p ¼ 0.91 (0.81e1.02)
0.10, Day of surgery 0.97 (0.88
e1.07), p ¼ 0.56
ICU length of stay (adjusted
odds ratio, 95% CI): both day of/
before surgery 1.12 (0.87
e1.45), p ¼ 0.15, Day before
surgery 0.92 (0.75e1.13) 0.44,
Day of surgery 1.04 (0.84
e1.29), p ¼ 0 0.69.
Infection, (adjusted odds ratio
95% CI): both day of/before
surgery 1.37 (0.81e2.33), p ¼ 0
0.25, day before surgery 1.56
(0.96e2.52), p ¼ 0.07, day of
surgery 1.07 (0.66e1.73),
p ¼ 0.78
Steroid dose and regimens not
reported.
No outcomes on inotrope
requirements, low cardiac
output syndrome, ﬂuid
retention or renal failure.
Elhoff et al., Oct. 2015,
Pediatr Crit Care
Med, USA (7)
549 neonates
underwent a Norwood
procedure were
included. Groups were
compared to determine
if outcomes differed
between intraoperative
steroid recipients
(n¼ 498, 91%) and non-
recipients (n ¼ 51, 9%).
Multicentre retrospective
study
(Level 3)
Discharged alive,
mechanical ventilation,
ICU and hospital length
of stay, renal failure,
extracorporeal
membrane
oxygenation (ECMO),
psychomotor
development index,
mental development
index.
Steroids vs. non steroid
recipients (univariate): hospital
survival (94% vs 83%, p ¼ 0.03),
ICU stays (16 days; IQR¼ 12e33
vs. 14 days, IQR ¼ 9e28;
p ¼ 0.04) and hospital stays (29
days; interquartile range, 21
e50 vs 23 days; interquartile
range, 15e40; p ¼ 0.01), ECMO
use: 54 (11%) vs. 2 (4%),p ¼ 0.15
infectious complication (197
(40%) vs. 23 (45%), p ¼ 0.44),
renal failure (44 (9%) vs. 2 (4%),
p ¼ 0.30, psychomotor
development index (72 (54
e92) vs. 75 (62e94), p ¼ 0.14,
mental development Index (92
(77e101) vs. 95 (84e103),
p ¼ 0.22.
In multivariate analysis,
hospital survival trended
toward favouring the non-
steroid groupwith an odds ratio
of 3.52 (95% CI, 0.98e12.64;
p ¼ 0.054) and lengths of stay
associations were no longer
signiﬁcant.
Steroid dose and regimens not
reported.
Dreher et al. Sept 2015,
J Extra Corpor
Technol (11)
222 children (55
neonates) undergoing
heart surgery without
methylprednisolone in
CPB prime were
compared to 303
children (58 neonates)
with
methylprednisolone
(30 mg/kg up to a
maximum dose of
500 mg).
Single centre retrospective
study
(Level 3)
Death prior to
discharge, wound
infection, intubation
reintubation,
respiratory failure
requiring
tracheostomy, length of
stay (days), renal
failure, postoperative
mechanical circulatory
support support.
Neonate outcome data for
steroid vs. no steroids: death
prior to discharge; 4 (7.27%) vs
6 (10.53%), p-value not
signiﬁcant (ns); any wound
infection: 4 (7.27%) vs. 1
(1.75%), p ¼ ns; intubation time
(days): 1.29 (0.11e58.27) vs
1.21 (0.1e11.07), p ¼ ns;
reintubation: 13 (24.07%) vs. 7
(12.96%), p ¼ ns; respiratory
failure requiring tracheostomy:
0 (0.00%) vs 0 (0.00%), p ¼ ns;
length of stay (days): 19 (5
e179) vs. 15 (3e71), p ¼ ns;
renal failure requiring dialysis:
0 (0.00%) vs. 0 (0.00%), p ¼ ns;
postoperative mechanical
circulatory support: 5 (9.09%)
vs. 6 (10.53%), p ¼ ns.
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Table 1 (continued )
Author, date and
country
Patient group Study type and level
of evidence
Outcomes Key results Comments
Ando et al., Ann Thorac
Surg, November
2005, Japan (12)
20 neonates
undergoing
biventricular repair
were enrolled; 10
patients received
hydrocortisone
infusion
(0.18 mg kg1 h1 for 3
days, 0.09 mg kg1 h1
for 2 days, and
0.045 mg kg1 h1 for 2
days) after
discontinuation of
cardiopulmonary by-
pass the other 10
received placebo.
Patient assignment was
manipulated so that
inter-anatomic
variations were
matched between the
two groups
Non-randomized
controlled
trial (Level 3)
Left ventricular
shortening fraction,
serum lactate level,
inotropic score, net
ﬂuid balance, A-a
gradient, duration of
mechanical ventilation,
creatinine, urine
output, radiologic soft
tissue index, blood
glucose, renal failure.
Placebo vs. hydrocortisone
group: left ventricular
shortening fraction (%):
19.0 ± 17.5 vs. 23.4 ± 13.2,
p ¼ 0.0203; inotropic score:
9.1 ± 3.0 vs. 7.6 ± 3.4,
p ¼ 0.043), serum lactate:
3.3 ± 1.0 vs. 2.3 ± 1.1,p ¼ 0.049;
net positive ﬂuid balance (ml/
kg): 15.4 ± 28.9 vs. 13.7 ± 24.9,
p ¼ 0.027, radiologic soft tissue
index: 2.0 ± 0.6 vs. 1.6 ± 0.4,
p ¼ 0.065, alveolarearterial
oxygen tension difference
(mmHg): 243.1 ± 72.0 vs.
361.2 ± 129.3; duration of
mechanical ventilation
(83.5 ± 42.1 versus
138.2 ± 89.7 h; p ¼ 0.098),
blood glucose: 108.7 ± 18.6 vs.
133.3 ± 45.9,p ¼ 0.152, urine
output (mL/kg): 63.1 ± 27.7 vs.
94.8 ± 41.6, p ¼ 0.063.
Both groups received
methylprednisolone, 30 mg/kg,
at induction.
No deaths in both groups.
D. Fudulu et al. / Annals of Medicine and Surgery 9 (2016) 67e71 71Funding
The study was supported by the British Heart Foundation and
the NIHR Bristol Cardiovascular Biomedical Research Unit.
References
[1] O.A. Khan, J. Dunning, A.C. Parvaiz, R. Agha, D. Rosin, K. Mackway-Jones, To-
wards evidence-based medicine in surgical practice: best BETs, Int. J. Surg. 9
(2011) 585e588. England: Copyright (c) 2011 Surgical Associates Ltd. Pub-
lished by Elsevier Ltd. All rights reserved.
[2] M.L. Green, J. Koch, Adrenocortical function in the postoperative pediatric
cardiac surgical patient, Curr. Opin. Pediatr. 24 (3) (2012) 285e290.
[3] S.K. Pasquali, M. Hall, J.S. Li, E.D. Peterson, J. Jaggers, A.J. Lodge, et al., Corti-
costeroids and outcome in children undergoing congenital heart surgery:
analysis of the pediatric health information systems database, Circulation 122
(21) (2010) 2123e2130.
[4] S.K. Pasquali, J.S. Li, X. He, M.L. Jacobs, S.M. O'Brien, M. Hall, et al., Perioperative
methylprednisolone and outcome in neonates undergoing heart surgery, Pe-
diatrics 129 (2) (2012) e385e91.
[5] S.M. Robert, S. Borasino, R.J. Dabal, D.C. Cleveland, K.M. Hock, J.A. Alten,
Postoperative hydrocortisone infusion reduces the prevalence of low cardiac
output syndrome after neonatal cardiopulmonary bypass, Pediatr. Crit. Care
Med. 16 (7) (2015) 629e636.[6] J. Keski-Nisula, E. Pesonen, K.T. Olkkola, K. Peltola, P.J. Neuvonen,
N. Tuominen, et al., Methylprednisolone in neonatal cardiac surgery: reduced
inﬂammation without improved clinical outcome, Ann. Thorac. Surg. 95 (6)
(2013) 2126e2132.
[7] J.J. Elhoff, S.M. Chowdhury, S.C. Zyblewski, A.M. Atz, S.M. Bradley,
E.M. Graham, Intraoperative steroid use and outcomes following the Norwood
procedure: an analysis of the pediatric heart network's public database,
Pediatr. Crit. care Med. A J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive
Crit. Care Soc. 17 (1) (2016) 30e35.
[8] M. Allen, S. Sundararajan, N. Pathan, M. Burmester, D. Macrae, Anti-inﬂam-
matory modalities: their current use in pediatric cardiac surgery in the United
Kingdom and Ireland, Pediatr. Crit. Care Med. 10 (3) (2009) 341e345.
[9] P.A. Checchia, R.A. Bronicki, J.M. Costello, D.P. Nelson, Steroid use before pe-
diatric cardiac operations using cardiopulmonary bypass: an international
survey of 36 centers, Pediatr. Crit. Care Med. 6 (4) (2005) 441e444.
[10] E.M. Graham, A.M. Atz, R.J. Butts, N.L. Baker, S.C. Zyblewski, R.L. Deardorff, et
al., Standardized preoperative corticosteroid treatment in neonates under-
going cardiac surgery: results from a randomized trial, J. Thorac. Cardiovasc.
Surg. 142 (6) (2011) 1523e1529.
[11] M. Dreher, A.C. Glatz, A. Kennedy, T. Rosenthal, J.W. Gaynor, A single-center
analysis of methylprednisolone use during pediatric cardiopulmonary bypass,
J. Extra-Corpor. Technol. 47 (3) (2015) 155e159.
[12] M. Ando, I.S. Park, N. Wada, Y. Takahashi, Steroid supplementation: a legiti-
mate pharmacotherapy after neonatal open heart surgery, Ann. Thorac. Surg.
80 (5) (2005) 1672e1678 discusison 8.
